Dexrazoxane for the treatment of chemotherapy-related side effects
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Dexrazoxane for the treatment of chemotherapy-related side effects. / Langer, Seppo W.
I: Cancer Management and Research, Bind 6, 2014, s. 357-63.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Dexrazoxane for the treatment of chemotherapy-related side effects
AU - Langer, Seppo W
PY - 2014
Y1 - 2014
N2 - For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
AB - For more than half a century, the different properties of dexrazoxane have captured the attention of scientists and clinicians. Presently, dexrazoxane is licensed in many parts of the world for two different indications: prevention of cardiotoxicity from anthracycline-based chemotherapy, and prevention of tissue injuries after extravasation of anthracyclines. This article reviews the historical, preclinical, and clinical background for the use of dexrazoxane for these indications.
U2 - 10.2147/CMAR.S47238
DO - 10.2147/CMAR.S47238
M3 - Review
C2 - 25246808
VL - 6
SP - 357
EP - 363
JO - Cancer Management and Research
JF - Cancer Management and Research
SN - 1179-1322
ER -
ID: 247891061